Clinical Trials Browser

Recurrence × Plasma cell × 30 days × Clear all

NCT05519085 2026-05-27

SUCCESSOR-1

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT05714839 2026-05-22

DREAMM-20

Phase 1/2 Recruiting

Multiple Myeloma, Recurrence

NCT06215118 2026-05-22

MagnetisMM-30

Phase 1 Recruiting

Multiple Myeloma, Recurrence

NCT07138209 2026-05-22

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT05911321 2026-05-20

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

Phase 2 Active not recruiting

6 enrolled 5 charts

Multiple Myeloma, Recurrence

NCT04824794 2026-05-19

GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies

Phase 1/2 Terminated

130 enrolled 40 charts

LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Recurrence, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse

NCT07116616 2026-05-18

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma, Recurrence

NCT06615479 2026-05-13

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT07579234 2026-05-12

A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT05652335 2026-05-08

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Phase 1 Recruiting

Amyloidosis, Multiple Myeloma, Recurrence

NCT06604715 2026-05-08

A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma, Recurrence

NCT04771572 2026-05-05

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Phase 1 Recruiting

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT05064358 2026-05-05

DREAMM 14

Phase 2 Completed

177 enrolled 37 charts

Multiple Myeloma, Recurrence

NCT02343042 2026-05-04

STOMP

Phase 1/2 Active not recruiting

Multiple Myeloma, Recurrence

NCT05927571 2026-05-04

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Phase 1 Recruiting

Multiple Myeloma, Recurrence